Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Graeme Moyle

Showing results (41-50 of 120) with videos related to

Pageof 12
Sort By:
Journal of Acquired Immune Deficiency Syndromes (1999)|January 3, 2025
Brief Report: Resolution of Neuropsychiatric Adverse Events After Switching to a Doravirine-Based Regimen in the Open-Label Extensions of the DRIVE-AHEAD and DRIVE-FORWARD TrialsGraeme Moyle, Fanxia Meng, Hong Wan, et al.
The AIDS Reader|December 10, 2008
Antiretroviral treatment update from the 17th International AIDS ConferenceBrian Boyle, Cal Cohen, Edwin DeJesus, et al.
Journal of the International AIDS Society|November 15, 2014
Effect of hyperbilirubinaemia on neurocognitive, renal, bone and cardiovascular markers in HIV infection treated with boosted protease inhibitorsTristan J Barber, Graeme Moyle, Andrew Hill, et al.
AIDS (London, England)|July 2, 2005
Early virologic failure in HIV-1 infected subjects on didanosine/tenofovir/efavirenz: 12-week results from a randomized trialDesmond Maitland, Graeme Moyle, James Hand, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 17, 2004
Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently: a cohort and case-control studyRachael Jones, Justin Stebbing, Mark Nelson, et al.
AIDS Research and Human Retroviruses|October 15, 2021
Short Communication: Predictive Value of HIV-Related Versus Traditional Risk Factors for Coronary Atherosclerosis in People Aging with HIVBranca Pereira, Maria Mazzitelli, Ana Milinkovic, et al.
The Journal of Antimicrobial Chemotherapy|July 31, 2014
Virological efficacy of abacavir: systematic review and meta-analysisMario Cruciani, Carlo Mengoli, Marina Malena, et al.
AIDS Care|June 4, 2021
Factors associated with overweight/obesity in a cohort of people living with HIV over 50 years of ageMaria Mazzitelli, Branca Isabel Pereira, Graeme Moyle, et al.
Antiviral Therapy|March 8, 2006
An open-label, randomized comparative pilot study of a single-class quadruple therapy regimen versus a 2-class triple therapy regimen for individuals initiating antiretroviral therapyGraeme Moyle, Christopher Higgs, Alastair Teague, et al.
Antiviral Therapy|April 18, 2014
Changes in biomarkers in HIV-1-infected treatment-naive patients treated with tenofovir DF/emtricitabine plus atazanavir/ritonavir or lopinavir/ritonavir for 96 weeks: the CASTLE biomarker substudyGraeme Moyle, Helene Hardy, Jonathan Uy, et al.
Pageof 12

Showing results (41-50 of 120) with videos related to

Sort By:
Pageof 12
Journal of Acquired Immune Deficiency Syndromes (1999)|January 3, 2025
Brief Report: Resolution of Neuropsychiatric Adverse Events After Switching to a Doravirine-Based Regimen in the Open-Label Extensions of the DRIVE-AHEAD and DRIVE-FORWARD TrialsGraeme Moyle, Fanxia Meng, Hong Wan, et al.
The AIDS Reader|December 10, 2008
Antiretroviral treatment update from the 17th International AIDS ConferenceBrian Boyle, Cal Cohen, Edwin DeJesus, et al.
Journal of the International AIDS Society|November 15, 2014
Effect of hyperbilirubinaemia on neurocognitive, renal, bone and cardiovascular markers in HIV infection treated with boosted protease inhibitorsTristan J Barber, Graeme Moyle, Andrew Hill, et al.
AIDS (London, England)|July 2, 2005
Early virologic failure in HIV-1 infected subjects on didanosine/tenofovir/efavirenz: 12-week results from a randomized trialDesmond Maitland, Graeme Moyle, James Hand, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 17, 2004
Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently: a cohort and case-control studyRachael Jones, Justin Stebbing, Mark Nelson, et al.
AIDS Research and Human Retroviruses|October 15, 2021
Short Communication: Predictive Value of HIV-Related Versus Traditional Risk Factors for Coronary Atherosclerosis in People Aging with HIVBranca Pereira, Maria Mazzitelli, Ana Milinkovic, et al.
The Journal of Antimicrobial Chemotherapy|July 31, 2014
Virological efficacy of abacavir: systematic review and meta-analysisMario Cruciani, Carlo Mengoli, Marina Malena, et al.
AIDS Care|June 4, 2021
Factors associated with overweight/obesity in a cohort of people living with HIV over 50 years of ageMaria Mazzitelli, Branca Isabel Pereira, Graeme Moyle, et al.
Antiviral Therapy|March 8, 2006
An open-label, randomized comparative pilot study of a single-class quadruple therapy regimen versus a 2-class triple therapy regimen for individuals initiating antiretroviral therapyGraeme Moyle, Christopher Higgs, Alastair Teague, et al.
Antiviral Therapy|April 18, 2014
Changes in biomarkers in HIV-1-infected treatment-naive patients treated with tenofovir DF/emtricitabine plus atazanavir/ritonavir or lopinavir/ritonavir for 96 weeks: the CASTLE biomarker substudyGraeme Moyle, Helene Hardy, Jonathan Uy, et al.
Pageof 12